Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01682577 |
Recruitment Status :
Completed
First Posted : September 11, 2012
Last Update Posted : September 11, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy | Drug: Perindopril 4 mg tablets of PT Dexa Medica Drug: Perindopril 4 mg tablets of Servier | Not Applicable |
The participating subjects were required to have an overnight fast and in the next morning were given orally one tablet of the test drug (Perindopril 4 mg tablets of PT Dexa Medica) or one tablet of the reference drug (Prexum® 4 mg, Servier).
Blood samples were drawn immediately before taking the drug (control), and at 20, 40 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 192 hours after drug administration.
Three weeks after the first drug administration (washout period), the procedure was repeated using the alternate drug.
The pharmacokinetic parameters, including AUCt, AUCinf, Cmax, t max, and t1/2, were determined based on the concentrations of the perindopril parent compound and the metabolite perindoprilat, using high-performance liquid chromatography method with tandem mass spectrometry detector (LC-MS/MS).
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Treatment |
Official Title: | Bioequivalence Study of 4 mg Perindopril Tablets Produced by PT Dexa Medica in Comparison With the Reference Tablets (Prexum® 4 mg, Servier)Under Fasting Condition |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | November 2008 |
Actual Study Completion Date : | December 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Perindopril 4 mg tablets of PT Dexa Medica
Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg. A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects. |
Drug: Perindopril 4 mg tablets of PT Dexa Medica
Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Other Names:
|
Active Comparator: Perindopril 4 mg tablets of Servier
Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg. A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects. |
Drug: Perindopril 4 mg tablets of Servier
Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Other Names:
|
- Area under concentration-time curve (AUC)of perindopril parent compound [ Time Frame: 192 hours ]Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of perindopril parent compound.
- Area under concentration-time curve (AUC)of perindoprilat [ Time Frame: 192 hours ]Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of the active metabolite, perindoprilat.
- Peak plasma concentration (Cmax)of perindopril parent compound [ Time Frame: 192 hours ]Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of perindopril parent compound.
- Peak plasma concentration (Cmax)of perindoprilat [ Time Frame: 192 hours ]Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of the active metabolite, perindoprilat.
- Time to achieve the peak plasma concentration (tmax)of perindopril parent compound [ Time Frame: 192 hours ]
- Time to achieve the peak plasma concentration (tmax)of perindoprilat [ Time Frame: 192 hours ]
- Elimination half-life (t1/2)of perindopril parent compound [ Time Frame: 192 hours ]
- Elimination half-life (t1/2)of perindoprilat [ Time Frame: 192 hours ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy male and female subjects
- Aged 18-55 years inclusive
- A body mass index in the range of 18-25 kg/m2
- Able to participate, communicate well with the investigators and willing to give informed consent
- Non-smokers
-
Vital signs (after 10 minutes resting) are within the following ranges:
- systolic blood pressure 100-125 mmHg
- diastolic blood pressure 60-80 mmHg
- pulse rate 60-90 bpm
Exclusion Criteria:
- Pregnant or lactating women
- Known hypersensitivity or contraindication to perindopril
- Intake of any prescription drug within 14 days of this study's first dosing day
- Intake of any non-prescription drug, food supplement, or herbal medicine within 7 days of this study's first dosing day
- History or presence of any liver dysfunction (ALT, alkaline phosphatase, total bilirubin ≥ 1.5 ULN)
- History of any bleeding or coagulation disorders
- Clinically significant ECG abnormalities
- Clinically significant haematology abnormalities
- Renal insufficiency (plasma creatinine concentration ≥ 1.4 mg/dL)
- Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug
- A donation or loss of 500 mL (or more) of blood within 3 months before this study's first dosing day
- A positive hepatitis B surface antigen (HBsAg), anti-HCV, and anti-HIV
- History of drug or alcohol abuse within 12 months prior to screening of this study
- Participation in a previous study within 3 months of this study's first dosing day

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01682577
Indonesia | |
PT Equilab International | |
Jakarta, Indonesia, 12430 |
Principal Investigator: | Danang A Yunaidi, MD | PT. Equilab International |
Responsible Party: | Dexa Medica Group |
ClinicalTrials.gov Identifier: | NCT01682577 |
Other Study ID Numbers: |
PR.122/EQL/2008 |
First Posted: | September 11, 2012 Key Record Dates |
Last Update Posted: | September 11, 2012 |
Last Verified: | September 2012 |
Perindopril Perindoprilat Bioequivalence Pharmacokinetic Angiotensin-converting enzyme inhibitor |
Perindopril Angiotensin-Converting Enzyme Inhibitors Protease Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antihypertensive Agents |